{"info": {"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 68, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": 6948244, "exercisedValue": 0, "unexercisedValue": 43528872}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 52, "title": "Vice Chairman & Pres", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 3998042, "exercisedValue": 0, "unexercisedValue": 13150419}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 54, "title": "Exec. VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 2972736, "exercisedValue": 0, "unexercisedValue": 5172329}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 59, "title": "Exec. VP of Operations", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 2576755, "exercisedValue": 0, "unexercisedValue": 28534760}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 53, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 2983231, "exercisedValue": 2777988, "unexercisedValue": 10864175}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 60, "title": "Sr. VP of R&D and Chief Scientific Officer", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "VP of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 56, "title": "Exec. VP & Chief HR Officer", "yearBorn": 1966, "fiscalYear": 2013, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carrie C. Strom", "age": 44, "title": "Sr. VP of AbbVie & Pres of Global Allergan Aesthetics", "yearBorn": 1978, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rae L. Livingston", "title": "Chief Equity Officer", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 161.18, "open": 161.0, "dayLow": 158.41, "dayHigh": 161.23, "regularMarketPreviousClose": 161.18, "regularMarketOpen": 161.0, "regularMarketDayLow": 158.41, "regularMarketDayHigh": 161.23, "dividendRate": 5.92, "dividendYield": 0.037100002, "exDividendDate": 1681344000, "payoutRatio": 0.8507, "fiveYearAvgDividendYield": 4.42, "beta": 0.553287, "trailingPE": 24.10725, "forwardPE": 14.325852, "volume": 4344119, "regularMarketVolume": 4344119, "averageVolume": 5987077, "averageVolume10days": 4234790, "averageDailyVolume10Day": 4234790, "bid": 158.31, "ask": 161.72, "bidSize": 900, "askSize": 900, "marketCap": 281539117056, "fiftyTwoWeekLow": 134.09, "fiftyTwoWeekHigh": 168.11, "priceToSalesTrailing12Months": 4.8496075, "fiftyDayAverage": 154.8582, "twoHundredDayAverage": 150.47646, "trailingAnnualDividendRate": 5.71, "trailingAnnualDividendYield": 0.035426233, "currency": "USD", "enterpriseValue": 337765531648, "profitMargins": 0.20388001, "floatShares": 1766657401, "sharesOutstanding": 1764140032, "sharesShort": 16277617, "sharesShortPriorMonth": 12704527, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.0092, "heldPercentInsiders": 0.0013, "heldPercentInstitutions": 0.71550006, "shortRatio": 2.42, "shortPercentOfFloat": 0.0092, "impliedSharesOutstanding": 0, "bookValue": 9.753, "priceToBook": 16.363169, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": -0.388, "netIncomeToCommon": 11781999616, "trailingEps": 6.62, "forwardEps": 11.14, "pegRatio": -6.02, "enterpriseToRevenue": 5.818, "enterpriseToEbitda": 10.864, "52WeekChange": 0.01844287, "SandP52WeekChange": -0.06829989, "lastDividendValue": 1.48, "lastDividendDate": 1681344000, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "messageBoardId": "finmb_141885706", "gmtOffSetMilliseconds": -14400000, "currentPrice": 159.59, "targetHighPrice": 200.0, "targetLowPrice": 135.0, "targetMeanPrice": 165.09, "targetMedianPrice": 163.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 23, "totalCash": 9228999680, "totalCashPerShare": 5.216, "ebitda": 31089000448, "totalDebt": 64583000064, "quickRatio": 0.693, "currentRatio": 0.964, "totalRevenue": 58054000640, "debtToEquity": 373.593, "revenuePerShare": 32.78, "returnOnAssets": 0.0991, "returnOnEquity": 0.72394997, "grossProfits": 41527000000, "freeCashflow": 22756999168, "operatingCashflow": 24942999552, "earningsGrowth": -0.388, "revenueGrowth": 0.016, "grossMargins": 0.71532, "ebitdaMargins": 0.53551996, "operatingMargins": 0.38966998, "financialCurrency": "USD", "trailingPegRatio": null}, "news": [{"uuid": "235df183-7091-3fab-84a1-94b54929713c", "title": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/abbvie-abbv-stock-sinks-market-214509809.html", "providerPublishTime": 1681854309, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HGBb_w3iAqceoCyVMucmoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV", "^GSPC"]}, {"uuid": "3a61271d-e444-38e4-9ab9-071804c44f6c", "title": "FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/fda-expands-abbvies-abbv-qulipta-161204097.html", "providerPublishTime": 1681834324, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4LSyP71ZcbNSV.s5ZrKdnA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6d12ae6d407957348a46f55b412dfc98", "width": 620, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/DHd9y1eBlWHslkAsFMJfDQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/6d12ae6d407957348a46f55b412dfc98", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV", "PFE", "NVO"]}, {"uuid": "ca1bc149-8969-356e-9c21-3bbd7055e635", "title": "Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/allergan-aesthetics-celebrates-journeys-women-140400975.html", "providerPublishTime": 1681826640, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZmBZR.LAK7CNeITLwzz_.A--~B/aD0xNTE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f18ed095f89a01b4787f729568c328c2", "width": 400, "height": 151, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/d.o16SAfXs6pN4uhTbALVQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f18ed095f89a01b4787f729568c328c2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV"]}, {"uuid": "e0035d5e-0ace-3a6c-b093-7f03364ba5fb", "title": "Are Investors Undervaluing AbbVie Inc. (NYSE:ABBV) By 42%?", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/investors-undervaluing-abbvie-inc-nyse-140035051.html", "providerPublishTime": 1681826435, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RXyD9y0cms.m7cbzIS4PQQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/B91qlhQfRNcLBJgBSzw7Zw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV"]}, {"uuid": "23da3603-0e18-344c-ac8f-121d9fa29e84", "title": "U.S. FDA Approves QULIPTA\u00ae (atogepant) for Adults With Chronic Migraine", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/u-fda-approves-qulipta-atogepant-234100408.html", "providerPublishTime": 1681774860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/PzhIB2MPTKJeTOU4rK5ssA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ffb3ce363c19a9e0e16639fb36a77d45", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6ERFAbBtTkUUJ_.krRK3wg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ffb3ce363c19a9e0e16639fb36a77d45", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV"]}, {"uuid": "89f8fb11-0ba5-3e53-ad2f-219e08e906d8", "title": "AbbVie Announces Provincial Reimbursement for VRAYLAR\u00ae (cariprazine) for the Treatment of Schizophrenia in Qu\u00e9bec", "publisher": "CNW Group", "link": "https://finance.yahoo.com/news/abbvie-announces-provincial-reimbursement-vraylar-120100828.html", "providerPublishTime": 1681732860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0UmNkCeodUAMuM_Ic2ykpA--~B/aD0yMDA7dz0zODc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/3f312fb17720134a4efa0776c96986e9", "width": 387, "height": 200, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NXQXL.43DWH_Aj8kfYCpdQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/cnwgroup.com/3f312fb17720134a4efa0776c96986e9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV"]}, {"uuid": "fa87371c-7f9f-3ffc-98ca-b98e9fa0622c", "title": "AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000311.html", "providerPublishTime": 1681711200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/t1a5TNrVVL7FMyrTw0QGKw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d7087b7dcf35b9de2e5764efb0ceba01", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tKPxfw1qvIl5v1M6QEVf4Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d7087b7dcf35b9de2e5764efb0ceba01", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ABBV"]}, {"uuid": "1cef805e-a5e9-39f1-87b4-e4af4959883d", "title": "Merck to Acquire Prometheus Biosciences", "publisher": "The Wall Street Journal", "link": "https://finance.yahoo.com/m/1cef805e-a5e9-39f1-87b4-e4af4959883d/merck-to-acquire-prometheus.html", "providerPublishTime": 1681683600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/yps4vQD8_MT.ArbbZtkIJw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e5fa7a8ac49f1ac7fbc29919da762252", "width": 1280, "height": 640, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/x5kV40fpWF2weWxfWRG8Cw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e5fa7a8ac49f1ac7fbc29919da762252", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RXDX", "AMGN", "MRK", "ABBV"]}]}